Jubilant Life gets USFDA nod for generic anti-depressant tablets
New Delhi: Jubilant Life Sciences Ltd has received final approval from the US health regulator for its generic version of anti-depressant Paxil tablets.The final approval for the abbreviated new drug application (ANDA) from the US Food and Drug Administration (USFDA) for Paroxetine tablets of Apotex is for strengths of 10 mg, 20 mg, 30 mg and 40 mg, the company said in a Bombay Stock...
Login or Register to read the full article
New Delhi: Jubilant Life Sciences Ltd has received final approval from the US health regulator for its generic version of anti-depressant Paxil tablets.
The final approval for the abbreviated new drug application (ANDA) from the US Food and Drug Administration (USFDA) for Paroxetine tablets of Apotex is for strengths of 10 mg, 20 mg, 30 mg and 40 mg, the company said in a Bombay Stock Exchange (BSE) filing.
As on September 30, 2015, Jubilant Life Sciences had a total of 820 filings for formulations, of which 391 have been approved in various regions globally.
"These include 71 ANDAs filed in the US, of which 39 have been approved and 46 Dossier filings in Europe," it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd